What is the official website of Tamro Baltics ?

The official website of Tamro Baltics is http://www.tamrobaltics.com.

What is Tamro Baltics's cybersecurity risk score?

Tamro Baltics has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Tamro Baltics experienced?

According to Rankiteo, Tamro Baltics currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Tamro Baltics been affected by any supply chain cyber incidents ?

According to Rankiteo, Tamro Baltics has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Tamro Baltics have SOC 2 Type 1 certification ?

According to Rankiteo, Tamro Baltics is not certified under SOC 2 Type 1.

Does Tamro Baltics have SOC 2 Type 2 certification ?

According to Rankiteo, Tamro Baltics does not hold a SOC 2 Type 2 certification.

Does Tamro Baltics comply with GDPR ?

According to Rankiteo, Tamro Baltics is not listed as GDPR compliant.

Does Tamro Baltics have PCI DSS certification ?

According to Rankiteo, Tamro Baltics does not currently maintain PCI DSS compliance.

Does Tamro Baltics comply with HIPAA ?

According to Rankiteo, Tamro Baltics is not compliant with HIPAA regulations.

Does Tamro Baltics have ISO 27001 certification ?

According to Rankiteo,Tamro Baltics is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Tamro Baltics operate in ?

Tamro Baltics operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Tamro Baltics have ?

Tamro Baltics employs approximately 244 people worldwide.

Does Tamro Baltics own any subsidiaries ?

Tamro Baltics presently has no subsidiaries across any sectors.

How many LinkedIn followers does Tamro Baltics have ?

Tamro Baltics's official LinkedIn profile has approximately 710 followers.

What is the NAICS classification code for Tamro Baltics ?

Tamro Baltics is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Tamro Baltics have a Crunchbase profile ?

No, Tamro Baltics does not have a profile on Crunchbase.

Does Tamro Baltics have a LinkedIn profile ?

Yes, Tamro Baltics maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/tamro.

How many cybersecurity incidents has Tamro Baltics experienced ?

As of September 5, 2026, Rankiteo reports that Tamro Baltics has not experienced any cybersecurity incidents.

How many peer or competitor companies does Tamro Baltics have ?

Tamro Baltics has an estimated 5,755 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Tamro Baltics

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Tamro Baltics Vendor Cyber Rating & Cyber Score

tamrobaltics.com

Add Your Compliance Badge

We are a pharmaceutical wholesale and retail company operating in the three Baltic States of Estonia, Latvia, and Lithuania. We are a part of PHOENIX Group, which operates in 29 countries. Some numbers about Tamro Baltics: - We have more than 1200 employees. - We cooperate with over 350 own and partner pharmacies. - We have a total operating performance of over €450 Million. At Tamro Baltics, our company‘s mission is simple: We help people live healthier and better lives. We aim to provide reliable and high-quality access to healthcare products with passion and responsibility. Our vision is to become the best-integrated healthcare provider in the Baltics. This requires providing each customer and partner with the best possible services

Tamro Baltics A.I CyberSecurity Scoring

Scoring History

Tamro Baltics

Tamro Baltics CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Tamro Baltics Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Tamro Baltics

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Tamro Baltics in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Tamro Baltics in 2026.

Incident Types Tamro Baltics vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Tamro Baltics in 2026.

Incident History - Tamro Baltics (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Tamro Baltics Subsidiaries

Tamro Baltics

Pharmaceutical Manufacturing

Website: http://www.tamrobaltics.com

Company Size: 1,001-5,000 employees

Tamro FinlandWholesale

PHOENIX group - Integrated Healthcare ProviderWholesale

BENU FarmaciaPharmaceutical Manufacturing

Gruppo ComifarTransportation, Logistics, Supply Chain and Storage

NomecoTransportation, Logistics, Supply Chain and Storage

BENU SlovenskoPharmaceutical Manufacturing

PHOENIX Pharma ItaliaWholesale

PHOENIX Medical Supplies LtdPharmaceutical Manufacturing

BENU BelgiumPharmaceutical Manufacturing

Help Net FarmaPharmaceutical Manufacturing

PHOENIX FarmacijaPharmaceutical Manufacturing

PHX IrelandPharmaceutical Manufacturing

FarmeximWholesale Drugs and Sundries

Pharmacies BENU SAPharmaceutical Manufacturing

PHOENIX Pharmahandel GmbH & Co KGWholesale

OCP PortugalWholesale

Kemofarmacija d.d.Wholesale

PHOENIX Pharma BulgariaPharmaceutical Manufacturing

PHOENIX Pharma Switzerland AGHealth and Human Services

PHOENIX Zdravotnícke zásobovanie, a.s.Wholesale

Apotek 1Pharmaceutical Manufacturing

EL PHARMA – PHOENIX group Representation ServicesHealth and Human Services

SOFIADISWholesale

PHOENIX BelgiumHospitals and Health Care

Tamro SwedenPharmaceutical Manufacturing

SmilaHospitals and Health Care

Loading…

Tamro Baltics Similar Companies

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Loading…

NEWS

Tamro Baltics CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86098

SUMMARY

ntop nDPI versions before 6.0 contain a heap buffer overflow vulnerability in the ndpi_json_string_escape function that writes beyond caller-supplied buffer boundaries. Attackers can trigger the overflow by supplying crafted network packet data including TLS SNI, HTTP headers, or DNS names that reach the vulnerable function, causing heap corruption.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:H/A:H

cvss4

Base Score: 8.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-86097

SUMMARY

PX4 Autopilot through 1.17.0 contains a null pointer dereference vulnerability in param_set_default_file() and param_set_backup_file() functions that allows attackers to crash the autopilot process. Attackers can invoke 'param select' or 'param select-backup' commands with no path argument from any PX4 shell to trigger the crash.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-86096

SUMMARY

PX4 Autopilot through 1.17.0 contains a use-after-free vulnerability in TemperatureCalibration::start() due to a race condition between task spawning and object deletion. Attackers can trigger the calibration process via shell commands to write to freed heap memory, corrupting unrelated objects or allocator metadata and destabilizing heap operations.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:H

cvss4

Base Score: 6.0

Complexity: HIGH

CVSS:4.0/AV:A/AC:H/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.2

Exploitability

1.6

REFERENCES

CVE-2026-86095

SUMMARY

Unidata netcdf-c through 4.10.1 contains an out-of-bounds write vulnerability in NC4_HDF5_inq_attname() that copies HDF5 attribute names into a fixed 256-byte buffer without length validation. Attackers can craft HDF5 files with oversized attribute names to overflow the destination buffer, causing memory corruption and crashes when applications enumerate attribute names.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-48019

SUMMARY

Laravel is a web application framework. Prior to versions 12.60.0 and 13.10.0, a CRLF injection vulnerability in Laravel's email validation, in combination with how Symfony Mailer and Symfony Mime handle certain character sequences, may allow an unauthenticated attacker to interfere with outbound email processing in applications that send mail to user-supplied addresses. This issue has been patched in versions 12.60.0 and 13.10.0.

Published

Date2026-09-04

Updated

Date2026-09-04

RISK INFORMATION (Score: 8.9)

cvss3

Base Score: 8.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…